In-House Insights: Managing Legal Strategy in Cross-Border Biotech
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
top cover
Edward Tung serves as both CEO and General Counsel of MyoMed Bio, a company developing Myoblast Transfer Therapy (MTT), a kind of regenerative medicine, for heart failure, Duchenne